Clinical trial · Interventional
Tumor Antigen-sensitized DC Vaccine As an Adjuvant Therapy for Esophagus Cancer
Research on the Transformation of Postoperative Adjuvant Therapy of Tumor Antigen-sensitized DC Vaccine Applied to Esophagus Cancer
NCT05023928CI-TRIAL-00087092completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this single center, single arm and prospective study is to explore the safety and efficacy of tumor antigen-sensitized DC vaccine in postoperative adjuvant treatment of esophageal cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma | Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Esophagus Cancer | Esophageal Neoplasm | PROBABILISTIC | 0.70 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Tumor antigen-sensitized DC vaccine | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Tumor antigen-sensitized DC vaccine
- description
- Tumor antigen-sensitized vaccine is administrated, 1-week interval, totally 2 times. 2-week later, Neo-antigen DC vaccine is administrated, 2-week interval, totally 5 times.
- interventionNames
- Biological: Tumor antigen-sensitized DC vaccine
Primary outcomes (1)
- measure
- Number of participants with treatment-related adverse events as events as assessed by CTCAE v4.0
- timeFrame
- 3 months after the last administration of cells
- description
- Number of participants with treatment-related adverse events as events as assessed by CTCAE v4.0
Secondary outcomes (1)
- measure
- Disease-free Survival
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Pathologically confirmed diagnosis of esophageal squamous cell carcinoma； * Immunotherapy for preoperative； * Karnofsky performance status 0-1; * The postoperative pathological stage is (y) Pt + and / or N + M0 according to AJCC 8th * Function of the main organs is normal; * Edition Patient's written informed consent Exclusion Criteria: * Tumor emergencies; * Abnormal coagulation function; * Contagious diseases, such as HIV, HBV, HCV infection; * Mental disorders; * Concomitant tumors; * Immunological co-morbidities
References
Publications (0)
Data not yet available
No reference posted for this study.